首页 > 最新文献

Arthritis Research & Therapy最新文献

英文 中文
A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases 贝叶斯模型分析炎症性风湿性肌肉骨骼疾病患者在非医疗转换情况下合并症与生物仿制药治疗保留率的关系
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-09-04 DOI: 10.1186/s13075-024-03386-7
Imke Redeker, Stefan Moustakis, Styliani Tsiami, Xenofon Baraliakos, David Kiefer, Ioana Andreica, Björn Buehring, Jürgen Braun, Uta Kiltz
To analyse clinical outcomes of a non-medical switch from originator adalimumab (ADA) to its ABP501 biosimilar (ABP) over 6 months in patients with inflammatory rheumatic musculoskeletal diseases (RMD) in relation to comorbidity as a risk factor for therapy discontinuation. RMD patients switching from originator ADA to ABP were identified from a large routine database from October 2018 onwards. Documented clinical data at the time of non-medical switching (baseline), and at 3 and 6 months were collected. Comorbidities were represented by the Charlson Comorbidity Index (CCI) at baseline and patients were categorized based on CCI > 0. Differences in the ABP retention rate over 6 months between patients with CCI = 0 and patients with CCI > 0 were analysed using Bayesian exponential regression. A total of 111 patients with axial spondyloarthritis (n = 68), rheumatoid arthritis (n = 23) and psoriatic arthritis (n = 15), were identified, 74.8% of whom had continued treatment with ABP after 6 months, while a smaller proportion had either switched to another ADA biosimilar (10.8%), switched back to originator ADA (7.2%), switched to a different biologic (3.6%), or dropped out (3.6%). At baseline, a CCI > 0 was found in 38% of patients. Cardiovascular comorbidities (40%) were most prevalent followed by diseases of the skin (33%), the gastrointestinal tract (20%) and the eye (20%). ABP treatment was continued after 6 months in 74% of patients with CCI = 0 and in 76% with CCI > 0. Bayesian analysis showed only a small difference (months) in the APB continuation rate between groups (estimate 0.0012, 95% credible interval (CrI) -0.0337 to 0.0361). Adjusting for age, sex, and disease subtype revealed somewhat shorter retention rates for patients with CCI > 0, but the distribution of the difference included 0 (estimate -0.0689, 95% CrI -0.2246 to 0.0234). In a non-medical switch scenario of RMD patients, there was no evidence for a considerable difference in ABP retention rates over 6 months between comorbidity groups.
目的:分析炎症性风湿性肌肉骨骼疾病(RMD)患者在6个月内从原研阿达木单抗(ADA)非医疗转换为其ABP501生物类似物(ABP)的临床结果与作为治疗中止风险因素的合并症的关系。从 2018 年 10 月起,从大型常规数据库中确定了从原研 ADA 转为 ABP 的 RMD 患者。收集了非医疗转换时(基线)以及 3 个月和 6 个月的记录临床数据。合并症用基线时的夏尔森合并症指数(CCI)表示,并根据 CCI > 0 对患者进行分类。使用贝叶斯指数回归分析了 CCI = 0 和 CCI > 0 患者 6 个月内 ABP 保持率的差异。结果发现,共有111名患有轴性脊柱关节炎(68人)、类风湿性关节炎(23人)和银屑病关节炎(15人)的患者,其中74.8%的患者在6个月后继续使用ABP治疗,而较小比例的患者要么转用了另一种ADA生物仿制药(10.8%),要么转回了原研ADA(7.2%),要么转用了其他生物制剂(3.6%),要么退出了治疗(3.6%)。基线时,38% 的患者 CCI > 0。心血管合并症(40%)最普遍,其次是皮肤病(33%)、胃肠道疾病(20%)和眼部疾病(20%)。74% 的 CCI = 0 患者和 76% 的 CCI > 0 患者在 6 个月后继续接受 ABP 治疗。贝叶斯分析显示,各组间的 APB 持续率仅有微小差异(月)(估计值 0.0012,95% 可信区间 (CrI) -0.0337 至 0.0361)。对年龄、性别和疾病亚型进行调整后发现,CCI > 0 的患者保留率更短一些,但差异的分布包括 0(估计值为 -0.0689,95% 可信区间为 -0.2246 至 0.0234)。在 RMD 患者的非医疗转换情景中,没有证据表明不同合并症组别在 6 个月的 ABP 保持率上存在显著差异。
{"title":"A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases","authors":"Imke Redeker, Stefan Moustakis, Styliani Tsiami, Xenofon Baraliakos, David Kiefer, Ioana Andreica, Björn Buehring, Jürgen Braun, Uta Kiltz","doi":"10.1186/s13075-024-03386-7","DOIUrl":"https://doi.org/10.1186/s13075-024-03386-7","url":null,"abstract":"To analyse clinical outcomes of a non-medical switch from originator adalimumab (ADA) to its ABP501 biosimilar (ABP) over 6 months in patients with inflammatory rheumatic musculoskeletal diseases (RMD) in relation to comorbidity as a risk factor for therapy discontinuation. RMD patients switching from originator ADA to ABP were identified from a large routine database from October 2018 onwards. Documented clinical data at the time of non-medical switching (baseline), and at 3 and 6 months were collected. Comorbidities were represented by the Charlson Comorbidity Index (CCI) at baseline and patients were categorized based on CCI > 0. Differences in the ABP retention rate over 6 months between patients with CCI = 0 and patients with CCI > 0 were analysed using Bayesian exponential regression. A total of 111 patients with axial spondyloarthritis (n = 68), rheumatoid arthritis (n = 23) and psoriatic arthritis (n = 15), were identified, 74.8% of whom had continued treatment with ABP after 6 months, while a smaller proportion had either switched to another ADA biosimilar (10.8%), switched back to originator ADA (7.2%), switched to a different biologic (3.6%), or dropped out (3.6%). At baseline, a CCI > 0 was found in 38% of patients. Cardiovascular comorbidities (40%) were most prevalent followed by diseases of the skin (33%), the gastrointestinal tract (20%) and the eye (20%). ABP treatment was continued after 6 months in 74% of patients with CCI = 0 and in 76% with CCI > 0. Bayesian analysis showed only a small difference (months) in the APB continuation rate between groups (estimate 0.0012, 95% credible interval (CrI) -0.0337 to 0.0361). Adjusting for age, sex, and disease subtype revealed somewhat shorter retention rates for patients with CCI > 0, but the distribution of the difference included 0 (estimate -0.0689, 95% CrI -0.2246 to 0.0234). In a non-medical switch scenario of RMD patients, there was no evidence for a considerable difference in ABP retention rates over 6 months between comorbidity groups.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"94 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142130731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 更正:S100蛋白是多关节幼年特发性关节炎患者阿帕他赛反应的潜在预测性生物标志物
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-08-31 DOI: 10.1186/s13075-024-03385-8
Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, Jordi Antón, Ruben Cuttica, Michael Henrickson, Ivan Foeldvari, Daniel J Kingsbury, Margarita Askelson, Jinqi Liu, Sumanta Mukherjee, Robert L Wong, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Alexei A Grom
<p><b>Correction: Arthritis Res Ther 26</b>,<b> 125 (2024)</b></p><p><b>https://doi.org/10.1186/s13075-024-03347-0</b></p><p>Following publication of the original article [1], the authors reported an error to Supplementary Material 2. Supplementary Material 2 was removed as the file was only for the reviewers’ reference and not meant to be published.</p><p>The original article [1] has been updated.</p><ol data-track-component="outbound reference" data-track-context="references section"><li data-counter="1."><p>Brunner HI, Schulert GS, Sproles A, et al. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Res Ther. 2024;26:125. https://doi.org/10.1186/s13075-024-03347-0.</p><p>Article PubMed PubMed Central Google Scholar </p></li></ol><p>Download references<svg aria-hidden="true" focusable="false" height="16" role="img" width="16"><use xlink:href="#icon-eds-i-download-medium" xmlns:xlink="http://www.w3.org/1999/xlink"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Division of Rheumatology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA</p><p>Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Michael Henrickson, Daniel J Lovell & Alexei A Grom</p></li><li><p>Hospital México Americano, Guadalajara, CREA, Mexico</p><p>Gabriel Vega Cornejo</p></li><li><p>Pediatric Rheumatology Department, Hospital Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain</p><p>Jordi Antón</p></li><li><p>Ruben Cuttica MD, Pediatric Rheumatology, Hospital General de Ninos Pedro de Elizalde, Buenos Aires, Argentina</p><p>Ruben Cuttica</p></li><li><p>Hamburg Centre for Pediatric and Adolescent Rheumatology, Schon Klinik Hamburg Eilbek, Hamburg, Germany</p><p>Ivan Foeldvari</p></li><li><p>Division of Rheumatology, Randall Children’s Hospital at Legacy Emanuel, Portland, OR, USA</p><p>Daniel J Kingsbury</p></li><li><p>Global Biometric Sciences, Bristol Myers Squibb, Princeton, NJ, USA</p><p>Margarita Askelson</p></li><li><p>Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA</p><p>Jinqi Liu & Sumanta Mukherjee</p></li><li><p>Bristol Myers Squibb, Immunology and Fibrosis, Princeton, NJ, USA</p><p>Robert L Wong</p></li><li><p>Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universita degli Studi di Genova, Genoa, Italy</p><p>Alberto Martini</p></li><li><p>IRCCS Istituto Giannina Gaslini, Gaslini Trial Centre/Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy</p><p>Nicolino Ruperto</p></li></ol><span>Authors</span><ol><li><span>Hermine I Brunner</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Grant S Schulert</span>View author publications<p>You can also search for this author in <span>PubM
如果文章的知识共享许可协议中没有包含相关材料,而您的使用意图又未得到法律法规的允许或超出了允许的使用范围,您需要直接从版权所有者处获得许可。要查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/。除非在数据的信用行中另有说明,否则创作共用公共领域专用免责声明 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文提供的数据。转载与许可引用本文Brunner, H.I., Schulert, G.S., Sproles, A. et al. Correction:S100蛋白作为多关节幼年特发性关节炎阿巴他赛普反应的潜在预测性生物标志物。Arthritis Res Ther 26, 154 (2024). https://doi.org/10.1186/s13075-024-03385-8Download citationPublished: 31 August 2024DOI: https://doi.org/10.1186/s13075-024-03385-8Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
{"title":"Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis","authors":"Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, Jordi Antón, Ruben Cuttica, Michael Henrickson, Ivan Foeldvari, Daniel J Kingsbury, Margarita Askelson, Jinqi Liu, Sumanta Mukherjee, Robert L Wong, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Alexei A Grom","doi":"10.1186/s13075-024-03385-8","DOIUrl":"https://doi.org/10.1186/s13075-024-03385-8","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Correction: Arthritis Res Ther 26&lt;/b&gt;,&lt;b&gt; 125 (2024)&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;https://doi.org/10.1186/s13075-024-03347-0&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Following publication of the original article [1], the authors reported an error to Supplementary Material 2. Supplementary Material 2 was removed as the file was only for the reviewers’ reference and not meant to be published.&lt;/p&gt;&lt;p&gt;The original article [1] has been updated.&lt;/p&gt;&lt;ol data-track-component=\"outbound reference\" data-track-context=\"references section\"&gt;&lt;li data-counter=\"1.\"&gt;&lt;p&gt;Brunner HI, Schulert GS, Sproles A, et al. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Res Ther. 2024;26:125. https://doi.org/10.1186/s13075-024-03347-0.&lt;/p&gt;&lt;p&gt;Article PubMed PubMed Central Google Scholar &lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;Download references&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/p&gt;&lt;h3&gt;Authors and Affiliations&lt;/h3&gt;&lt;ol&gt;&lt;li&gt;&lt;p&gt;Division of Rheumatology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA&lt;/p&gt;&lt;p&gt;Hermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Michael Henrickson, Daniel J Lovell &amp; Alexei A Grom&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Hospital México Americano, Guadalajara, CREA, Mexico&lt;/p&gt;&lt;p&gt;Gabriel Vega Cornejo&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Pediatric Rheumatology Department, Hospital Sant Joan de Deu, Universitat de Barcelona, Barcelona, Spain&lt;/p&gt;&lt;p&gt;Jordi Antón&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Ruben Cuttica MD, Pediatric Rheumatology, Hospital General de Ninos Pedro de Elizalde, Buenos Aires, Argentina&lt;/p&gt;&lt;p&gt;Ruben Cuttica&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Hamburg Centre for Pediatric and Adolescent Rheumatology, Schon Klinik Hamburg Eilbek, Hamburg, Germany&lt;/p&gt;&lt;p&gt;Ivan Foeldvari&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Division of Rheumatology, Randall Children’s Hospital at Legacy Emanuel, Portland, OR, USA&lt;/p&gt;&lt;p&gt;Daniel J Kingsbury&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Global Biometric Sciences, Bristol Myers Squibb, Princeton, NJ, USA&lt;/p&gt;&lt;p&gt;Margarita Askelson&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA&lt;/p&gt;&lt;p&gt;Jinqi Liu &amp; Sumanta Mukherjee&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Bristol Myers Squibb, Immunology and Fibrosis, Princeton, NJ, USA&lt;/p&gt;&lt;p&gt;Robert L Wong&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universita degli Studi di Genova, Genoa, Italy&lt;/p&gt;&lt;p&gt;Alberto Martini&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;IRCCS Istituto Giannina Gaslini, Gaslini Trial Centre/Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy&lt;/p&gt;&lt;p&gt;Nicolino Ruperto&lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;span&gt;Authors&lt;/span&gt;&lt;ol&gt;&lt;li&gt;&lt;span&gt;Hermine I Brunner&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubMed&lt;span&gt; &lt;/span&gt;Google Scholar&lt;/span&gt;&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;Grant S Schulert&lt;/span&gt;View author publications&lt;p&gt;You can also search for this author in &lt;span&gt;PubM","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"7 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142100621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. 使用托法替尼治疗类风湿性关节炎患者严重感染的机器学习预测和解释模型。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-08-27 DOI: 10.1186/s13075-024-03376-9
Merete Lund Hetland, Anja Strangfeld, Gianluca Bonfanti, Dimitrios Soudis, J Jasper Deuring, Roger A Edwards

Background: Patients with rheumatoid arthritis (RA) have an increased risk of developing serious infections (SIs) vs. individuals without RA; efforts to predict SIs in this patient group are ongoing. We assessed the ability of different machine learning modeling approaches to predict SIs using baseline data from the tofacitinib RA clinical trials program.

Methods: This analysis included data from 19 clinical trials (phase 2, n = 10; phase 3, n = 6; phase 3b/4, n = 3). Patients with RA receiving tofacitinib 5 or 10 mg twice daily (BID) were included in the analysis; patients receiving tofacitinib 11 mg once daily were considered as tofacitinib 5 mg BID. All available patient-level baseline variables were extracted. Statistical and machine learning methods (logistic regression, support vector machines with linear kernel, random forest, extreme gradient boosting trees, and boosted trees) were implemented to assess the association of baseline variables with SI (logistic regression only), and to predict SI using selected baseline variables using 5-fold cross-validation. Missing values were handled individually per prediction model.

Results: A total of 8404 patients with RA treated with tofacitinib were eligible for inclusion (15,310 patient-years of total follow-up) of which 473 patients reported SIs. Amongst other baseline factors, age, previous infection, and corticosteroid use were significantly associated with SI. When applying prediction modeling for SI across data from all studies, the area under the receiver operating characteristic (AUROC) curve ranged from 0.656 to 0.739. AUROC values ranged from 0.599 to 0.730 in data from phase 3 and 3b/4 studies, and from 0.563 to 0.643 in data from ORAL Surveillance only.

Conclusions: Baseline factors associated with SIs in the tofacitinib RA clinical trial program were similar to established SI risk factors associated with advanced treatments for RA. Furthermore, while model performance in predicting SI was similar to other published models, this did not meet the threshold for accurate prediction (AUROC > 0.85). Thus, predicting the occurrence of SIs at baseline remains challenging and may be complicated by the changing disease course of RA over time. Inclusion of other patient-associated and healthcare delivery-related factors and harmonization of the duration of studies included in the models may be required to improve prediction.

Trial registration: ClinicalTrials.gov: NCT00147498; NCT00413660; NCT00550446; NCT00603512; NCT00687193; NCT01164579; NCT00976599; NCT01059864; NCT01359150; NCT02147587; NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT01039688; NCT02187055; NCT02831855; NCT02092467.

背景:类风湿性关节炎(RA)患者发生严重感染(SIs)的风险比没有RA的患者高;预测该患者群体SIs的工作正在进行中。我们利用托法替尼 RA 临床试验项目的基线数据评估了不同机器学习建模方法预测 SI 的能力:该分析包括来自 19 项临床试验(2 期,n = 10;3 期,n = 6;3b/4 期,n = 3)的数据。接受托法替尼5或10毫克、每日两次(BID)治疗的RA患者被纳入分析;接受托法替尼11毫克、每日一次治疗的患者被视为托法替尼5毫克、每日两次。提取了所有可用的患者水平基线变量。采用统计和机器学习方法(逻辑回归、线性核支持向量机、随机森林、极梯度提升树和提升树)评估基线变量与 SI 的关联(仅逻辑回归),并使用选定的基线变量通过 5 倍交叉验证预测 SI。每个预测模型单独处理缺失值:共有8404名接受托法替尼治疗的RA患者符合纳入条件(总随访时间为15310患者年),其中473名患者报告了SI。在其他基线因素中,年龄、既往感染和皮质类固醇的使用与SI显著相关。在对所有研究数据进行 SI 预测建模时,接收者操作特征曲线下面积 (AUROC) 为 0.656 至 0.739。3期和3b/4期研究数据的AUROC值介于0.599至0.730之间,仅ORAL监测数据的AUROC值介于0.563至0.643之间:结论:托法替尼RA临床试验项目中与SI相关的基线因素与已确定的与RA晚期治疗相关的SI风险因素相似。此外,虽然预测SI的模型性能与其他已发表的模型相似,但并未达到准确预测的阈值(AUROC > 0.85)。因此,预测基线SI的发生仍然具有挑战性,而且随着时间的推移,RA的病程变化可能会使预测变得更加复杂。可能需要纳入其他患者相关因素和医疗服务相关因素,并统一模型中的研究持续时间,以提高预测效果:试验注册:ClinicalTrials.gov:NCT00147498;NCT00413660;NCT00550446;NCT00603512;NCT00687193;NCT01164579;NCT00976599;NCT01059864;NCT01359150;NCT02147587;NCT00960440;NCT00847613;NCT00814307;NCT00856544;NCT00853385;NCT01039688;NCT02187055;NCT02831855;NCT02092467。
{"title":"Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib.","authors":"Merete Lund Hetland, Anja Strangfeld, Gianluca Bonfanti, Dimitrios Soudis, J Jasper Deuring, Roger A Edwards","doi":"10.1186/s13075-024-03376-9","DOIUrl":"10.1186/s13075-024-03376-9","url":null,"abstract":"<p><strong>Background: </strong>Patients with rheumatoid arthritis (RA) have an increased risk of developing serious infections (SIs) vs. individuals without RA; efforts to predict SIs in this patient group are ongoing. We assessed the ability of different machine learning modeling approaches to predict SIs using baseline data from the tofacitinib RA clinical trials program.</p><p><strong>Methods: </strong>This analysis included data from 19 clinical trials (phase 2, n = 10; phase 3, n = 6; phase 3b/4, n = 3). Patients with RA receiving tofacitinib 5 or 10 mg twice daily (BID) were included in the analysis; patients receiving tofacitinib 11 mg once daily were considered as tofacitinib 5 mg BID. All available patient-level baseline variables were extracted. Statistical and machine learning methods (logistic regression, support vector machines with linear kernel, random forest, extreme gradient boosting trees, and boosted trees) were implemented to assess the association of baseline variables with SI (logistic regression only), and to predict SI using selected baseline variables using 5-fold cross-validation. Missing values were handled individually per prediction model.</p><p><strong>Results: </strong>A total of 8404 patients with RA treated with tofacitinib were eligible for inclusion (15,310 patient-years of total follow-up) of which 473 patients reported SIs. Amongst other baseline factors, age, previous infection, and corticosteroid use were significantly associated with SI. When applying prediction modeling for SI across data from all studies, the area under the receiver operating characteristic (AUROC) curve ranged from 0.656 to 0.739. AUROC values ranged from 0.599 to 0.730 in data from phase 3 and 3b/4 studies, and from 0.563 to 0.643 in data from ORAL Surveillance only.</p><p><strong>Conclusions: </strong>Baseline factors associated with SIs in the tofacitinib RA clinical trial program were similar to established SI risk factors associated with advanced treatments for RA. Furthermore, while model performance in predicting SI was similar to other published models, this did not meet the threshold for accurate prediction (AUROC > 0.85). Thus, predicting the occurrence of SIs at baseline remains challenging and may be complicated by the changing disease course of RA over time. Inclusion of other patient-associated and healthcare delivery-related factors and harmonization of the duration of studies included in the models may be required to improve prediction.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT00147498; NCT00413660; NCT00550446; NCT00603512; NCT00687193; NCT01164579; NCT00976599; NCT01059864; NCT01359150; NCT02147587; NCT00960440; NCT00847613; NCT00814307; NCT00856544; NCT00853385; NCT01039688; NCT02187055; NCT02831855; NCT02092467.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"26 1","pages":"153"},"PeriodicalIF":4.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of risk factors and development of a nomogram prediction model for renal tubular acidosis in primary Sjogren syndrome patients 分析原发性 Sjogren 综合征患者肾小管酸中毒的风险因素并建立提名图预测模型
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-08-22 DOI: 10.1186/s13075-024-03383-w
Yanzhen Zeng, Runzhi Liu, Shuyi Li, Jingwen Wei, Fei Luo, Yongkang Chen, Dongmei Zhou
To investigate the risk factors of renal tubular acidosis (RTA) in patients with primary Sjögren’s syndrome (pSS) and create a personalized nomogram for predicting pSS-RTA patients. Data from 99 pSS patients who underwent inpatient treatment at our hospital from January 2012 to January 2024 were retrospectively collected and analyzed. Bootstrap resampling technique, single-factor, and multi-factor logistic regression analyses were used to explore the risk factors for pSS-RTA. A nomogram was developed based on the results of the multivariate logistic model. The model was evaluated through receiver operating characteristic curve, C-index, calibration curve, and decision curve analysis. In addition, we graded the severity of pSS-RTA patients and used univariate analysis to assess the relationship between pSS-RTA severity and risk factors. A multivariate logistic regression analysis revealed that concurrent thyroid disease, long symptom duration, subjective dry mouth, and positive RF were independent risk factors for pSS-RTA patients. Based on them, a personalized nomogram predictive model was established. With a p-value of 0.657 from the Hosmer-Lemeshow test, the model demonstrated a good fit. The AUC values in the training and validation groups were 0.912 and 0.896, indicating a strong discriminative power of the nomogram. The calibration curves for the training and validation groups closely followed the diagonal line with a slope of 1, confirming the model’s reliable predictive ability. Furthermore, the decision curve analysis showed that the nomogram model had a net benefit in predicting pSS-RTA, emphasizing its clinical value.This study did not find an association between the severity of pSS-RTA and risk factors. We developed a nomogram to predict RTA occurrence in pSS patients, and it is believed to provide a foundation for early identification and intervention for high-risk pSS patients. • Having thyroid disease, experiencing prolonged symptoms, reporting subjective dry mouth, and testing positive for rheumatoid factor (RF) were independent risk factors for pSS-RTA patients. • According to the nomogram, the probability of pSS-RTA patients can be identified. • Multi-centre studies and the inclusion of more quantitative indicators may lead to better predictive models.
研究原发性斯约格伦综合征(pSS)患者发生肾小管酸中毒(RTA)的危险因素,并建立预测pSS-RTA患者的个性化提名图。本研究回顾性收集并分析了2012年1月至2024年1月期间在我院接受住院治疗的99名pSS患者的数据。采用 Bootstrap 重采样技术、单因素和多因素逻辑回归分析来探讨 pSS-RTA 的风险因素。根据多变量逻辑模型的结果建立了一个提名图。通过接收者操作特征曲线、C-指数、校准曲线和决策曲线分析对模型进行了评估。此外,我们还对 pSS-RTA 患者的严重程度进行了分级,并使用单变量分析评估了 pSS-RTA 严重程度与风险因素之间的关系。多变量逻辑回归分析显示,并发甲状腺疾病、症状持续时间长、主观口干和 RF 阳性是 pSS-RTA 患者的独立风险因素。在此基础上,建立了个性化的提名图预测模型。经 Hosmer-Lemeshow 检验,该模型的拟合度为 0.657。训练组和验证组的 AUC 值分别为 0.912 和 0.896,表明提名图具有很强的判别能力。训练组和验证组的校准曲线紧贴斜率为 1 的对角线,证明该模型具有可靠的预测能力。此外,决策曲线分析表明,提名图模型在预测 pSS-RTA 方面有净获益,强调了其临床价值。我们建立了一个预测pSS患者RTA发生的提名图,相信它能为早期识别和干预高危pSS患者奠定基础。- 患有甲状腺疾病、症状持续时间长、主观口干、类风湿因子(RF)检测阳性是 pSS-RTA 患者的独立危险因素。- 根据提名图,可以确定 pSS-RTA 患者的概率。- 多中心研究和纳入更多量化指标可能会产生更好的预测模型。
{"title":"Analysis of risk factors and development of a nomogram prediction model for renal tubular acidosis in primary Sjogren syndrome patients","authors":"Yanzhen Zeng, Runzhi Liu, Shuyi Li, Jingwen Wei, Fei Luo, Yongkang Chen, Dongmei Zhou","doi":"10.1186/s13075-024-03383-w","DOIUrl":"https://doi.org/10.1186/s13075-024-03383-w","url":null,"abstract":"To investigate the risk factors of renal tubular acidosis (RTA) in patients with primary Sjögren’s syndrome (pSS) and create a personalized nomogram for predicting pSS-RTA patients. Data from 99 pSS patients who underwent inpatient treatment at our hospital from January 2012 to January 2024 were retrospectively collected and analyzed. Bootstrap resampling technique, single-factor, and multi-factor logistic regression analyses were used to explore the risk factors for pSS-RTA. A nomogram was developed based on the results of the multivariate logistic model. The model was evaluated through receiver operating characteristic curve, C-index, calibration curve, and decision curve analysis. In addition, we graded the severity of pSS-RTA patients and used univariate analysis to assess the relationship between pSS-RTA severity and risk factors. A multivariate logistic regression analysis revealed that concurrent thyroid disease, long symptom duration, subjective dry mouth, and positive RF were independent risk factors for pSS-RTA patients. Based on them, a personalized nomogram predictive model was established. With a p-value of 0.657 from the Hosmer-Lemeshow test, the model demonstrated a good fit. The AUC values in the training and validation groups were 0.912 and 0.896, indicating a strong discriminative power of the nomogram. The calibration curves for the training and validation groups closely followed the diagonal line with a slope of 1, confirming the model’s reliable predictive ability. Furthermore, the decision curve analysis showed that the nomogram model had a net benefit in predicting pSS-RTA, emphasizing its clinical value.This study did not find an association between the severity of pSS-RTA and risk factors. We developed a nomogram to predict RTA occurrence in pSS patients, and it is believed to provide a foundation for early identification and intervention for high-risk pSS patients. • Having thyroid disease, experiencing prolonged symptoms, reporting subjective dry mouth, and testing positive for rheumatoid factor (RF) were independent risk factors for pSS-RTA patients. • According to the nomogram, the probability of pSS-RTA patients can be identified. • Multi-centre studies and the inclusion of more quantitative indicators may lead to better predictive models.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"84 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142021842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy 特发性炎症性肌病患者体内抗 Ro-52 抗体与间质性肺病发生的关系
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-08-22 DOI: 10.1186/s13075-024-03382-x
Chia-Tse Weng, Tang-Hsiu Huang, Chun-Hsin Wu, Yuan-Ting Sun
Anti-Ro-52 antibodies have been associated with interstitial lung disease (ILD) in various autoimmune diseases. However, their role in ILD among patients with idiopathic inflammatory myopathies (IIMs) is relatively underexplored. This study aimed to investigate the association between anti-Ro-52 antibodies and the occurrence of ILD in individuals with IIMs. This retrospective observational study included 604 patients who underwent myositis autoantibody testing between July 2018 and January 2021 at our hospital and were diagnosed with either IIMs or IIM-mimics. Comparative analyses were conducted between IIMs and IIM-mimics, as well as within the IIM group between cases with and without ILD. Logistic regression or Firth’s logistic regression analyses were employed to assess the risk of ILD development in different IIM subgroups and myositis antibody categories. This study included 190 patients with IIM and 414 patients with IIM-mimics. Patients with IIM demonstrated higher incidence of ILD, concurrent autoimmune disease, and a greater likelihood of various myositis autoantibodies when compared to the IIM-mimics group. Within the IIM patient cohort, those with ILD exhibited a later age of onset of IIM, an increased mortality rate, and a more frequent presence of anti-aminoacyl-tRNA synthetase (ARS) antibodies compared to those without ILD. The presence of any myositis-specific antibody (MSA) was associated with a six-fold increased risk of ILD, while dual positivity for MSA and anti-Ro-52 antibodies conferred a twenty-fold risk. Anti-ARS antibodies carried a 14-fold increased risk of ILD, which escalated to 38-fold in cases of dual positivity for anti-ARS and anti-Ro-52 antibodies. Anti-Ro-52 antibodies alone increased the risk eight-fold. Among patients with IIM, the presence of ILD was linked to higher mortality. Certain autoantibodies, notably anti-ARS and anti-Ro-52 antibodies, were associated with an increased risk of ILD. The greatest risk of ILD was observed in cases of dual positivity for anti-ARS and anti-Ro-52 antibodies.
抗Ro-52抗体与各种自身免疫性疾病中的间质性肺病(ILD)有关。然而,在特发性炎症性肌病(IIMs)患者中,抗Ro-52抗体在间质性肺病中的作用还相对缺乏研究。本研究旨在探讨抗Ro-52抗体与特发性炎症性肌病患者ILD发生之间的关系。这项回顾性观察研究纳入了2018年7月至2021年1月期间在我院接受肌炎自身抗体检测并被诊断为IIMs或IIM-mimics的604名患者。在IIMs和IIM-mimics之间,以及在IIM组内有ILD和无ILD的病例之间进行了比较分析。采用逻辑回归或 Firth 逻辑回归分析来评估不同 IIM 亚组和肌炎抗体类别中发生 ILD 的风险。这项研究包括190名IIM患者和414名IIM-mimics患者。与IIM-mimics组相比,IIM患者的ILD发病率更高,并发自身免疫性疾病更多,各种肌炎自身抗体的可能性也更大。在IIM患者队列中,与无ILD的患者相比,有ILD的患者IIM发病年龄较晚,死亡率较高,抗氨基酸-tRNA合成酶(ARS)抗体出现的频率较高。任何肌炎特异性抗体(MSA)的存在都会导致罹患ILD的风险增加6倍,而MSA和抗Ro-52抗体双重阳性则会导致罹患ILD的风险增加20倍。抗ARS抗体阳性者患ILD的风险增加14倍,抗ARS和抗Ro-52抗体双重阳性者患ILD的风险增加38倍。仅抗Ro-52抗体就会使风险增加8倍。在IIM患者中,ILD的存在与较高的死亡率有关。某些自身抗体,尤其是抗-ARS和抗-Ro-52抗体,与ILD风险增加有关。在抗-ARS和抗-Ro-52抗体双重阳性的病例中,发生ILD的风险最大。
{"title":"Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy","authors":"Chia-Tse Weng, Tang-Hsiu Huang, Chun-Hsin Wu, Yuan-Ting Sun","doi":"10.1186/s13075-024-03382-x","DOIUrl":"https://doi.org/10.1186/s13075-024-03382-x","url":null,"abstract":"Anti-Ro-52 antibodies have been associated with interstitial lung disease (ILD) in various autoimmune diseases. However, their role in ILD among patients with idiopathic inflammatory myopathies (IIMs) is relatively underexplored. This study aimed to investigate the association between anti-Ro-52 antibodies and the occurrence of ILD in individuals with IIMs. This retrospective observational study included 604 patients who underwent myositis autoantibody testing between July 2018 and January 2021 at our hospital and were diagnosed with either IIMs or IIM-mimics. Comparative analyses were conducted between IIMs and IIM-mimics, as well as within the IIM group between cases with and without ILD. Logistic regression or Firth’s logistic regression analyses were employed to assess the risk of ILD development in different IIM subgroups and myositis antibody categories. This study included 190 patients with IIM and 414 patients with IIM-mimics. Patients with IIM demonstrated higher incidence of ILD, concurrent autoimmune disease, and a greater likelihood of various myositis autoantibodies when compared to the IIM-mimics group. Within the IIM patient cohort, those with ILD exhibited a later age of onset of IIM, an increased mortality rate, and a more frequent presence of anti-aminoacyl-tRNA synthetase (ARS) antibodies compared to those without ILD. The presence of any myositis-specific antibody (MSA) was associated with a six-fold increased risk of ILD, while dual positivity for MSA and anti-Ro-52 antibodies conferred a twenty-fold risk. Anti-ARS antibodies carried a 14-fold increased risk of ILD, which escalated to 38-fold in cases of dual positivity for anti-ARS and anti-Ro-52 antibodies. Anti-Ro-52 antibodies alone increased the risk eight-fold. Among patients with IIM, the presence of ILD was linked to higher mortality. Certain autoantibodies, notably anti-ARS and anti-Ro-52 antibodies, were associated with an increased risk of ILD. The greatest risk of ILD was observed in cases of dual positivity for anti-ARS and anti-Ro-52 antibodies.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"1 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142022048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort 纳入纤维素性坏死可提高滑膜组织评估在预测甲氨蝶呤反应方面的准确性:对 UCLouvain 布鲁塞尔 ERA 队列的分析
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-08-19 DOI: 10.1186/s13075-024-03384-9
Francesco Natalucci, Clément Triaille, Cécile Van Mullem, Tatiana Sokolova, Emilie Sapart, Laurent Meric de Bellefon, Adrien Nzeusseu, Christine Galant, Bernard Lauwerys, Patrick Durez
Rheumatoid Arthritis (RA) often exhibits suboptimal treatment response despite early diagnosis and treatment. This study aimed to analyze Early Rheumatoid Arthritis (ERA) synovial biopsies through histology and immunohistochemistry (IHC) to identify predictive factors for treatment response to Methotrexate (MTX). 140 ERA patients from the UCLouvain Arthritis Cohort underwent synovial biopsy and were monitored after initiating Disease-Modifying Antirheumatic Drug (DMARD) therapy. Histological features [Synovial Hyperplasia, Fibrinoid Necrosis (FN), Hypervascularization and Inflammatory Infiltrate] and IHC (CD3, CD20, CD138, CD68) were each semi-quantitatively assessed on a 0–3 scale with 7 levels. A strong association was observed between synovial CD68 and Fibrinoid Necrosis scores [r = 0.44 (0.27 − 0.56); p < 0.0001]. CD68 correlated with C-Reactive Protein (CRP), DAS28, SDAI and CDAI. Fibrinoid Necrosis score correlated with CRP and DAS28. Patients were then categorized as CD68NecrosisHIGH (CD68 + Necrosis ≥ 3) and CD68NecrosisLOW (CD68 + Necrosis < 3). CD68NecrosisHIGH exhibited higher pre-treatment disease activity [5.48 (1.6) versus 4.8 (1.7); p = 0.03] and a greater fall in DAS28 [1.99 (2.06) versus 1.1 (2.27), p = 0.03], SDAI [21.45 (IQR 23.3) versus 11.65 (IQR 17.5); p = 0.003] and CDAI [16 [14.9] versus 10.5 (20.1), p = 0.04]. CD68NecrosisHIGH patients had a higher EULAR Moderate/Good Response rate. CD68Necrosis score was incorporated into a probability matrix model together with clinical features (SJC44 and DAS28) to predict achieving a Moderate/Good EULAR Response Criteria at 3 months with a good performance (AUC 0.724). FN and CD68 + in ERA synovial biopsies identify patients with higher disease activity and predict a better treatment response at three months. A model including synovial CD68 and fibrinoid necrosis with baseline clinical features predicts EULAR response at 3 months.
类风湿性关节炎(RA)尽管可以早期诊断和治疗,但其治疗反应往往不尽如人意。本研究旨在通过组织学和免疫组织化学(IHC)分析早期类风湿性关节炎(ERA)滑膜活检,以确定甲氨蝶呤(MTX)治疗反应的预测因素。来自 UCLouvain 关节炎队列的 140 名ERA 患者接受了滑膜活检,并在开始使用改变病情抗风湿药(DMARD)治疗后接受了监测。组织学特征[滑膜增生、纤溶性坏死(FN)、血管增生和炎性浸润]和 IHC(CD3、CD20、CD138、CD68)均按 0-3 级的 7 个等级进行半定量评估。滑膜 CD68 与纤溶坏死评分之间存在密切联系[r = 0.44 (0.27 - 0.56); p < 0.0001]。CD68与C反应蛋白(CRP)、DAS28、SDAI和CDAI相关。纤溶坏死评分与 CRP 和 DAS28 相关。然后将患者分为 CD68NecrosisHIGH(CD68 + 坏死≥ 3)和 CD68NecrosisLOW(CD68 + 坏死< 3)两类。CD68NecrosisHIGH 在治疗前表现出更高的疾病活动度 [5.48 (1.6) 对 4.8 (1.7); p = 0.03],DAS28 下降幅度更大 [1.99 (2. 06) 对 1.1 (2. 06)]。06) 对 1.1 (2.27), p = 0.03]、SDAI [21.45 (IQR 23.3) 对 11.65 (IQR 17.5); p = 0.003]和 CDAI [16 [14.9] 对 10.5 (20.1), p = 0.04]。CD68NecrosisHIGH 患者的 EULAR 中度/良好反应率更高。CD68Necrosis评分与临床特征(SJC44和DAS28)一起被纳入概率矩阵模型,以预测3个月后达到EULAR中度/良好反应标准的情况,效果良好(AUC 0.724)。ERA滑膜活检中的FN和CD68 +可识别疾病活动性较高的患者,并预测3个月后的治疗反应。包括滑膜 CD68 和纤维坏死以及基线临床特征在内的模型可预测 3 个月后的 EULAR 反应。
{"title":"Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort","authors":"Francesco Natalucci, Clément Triaille, Cécile Van Mullem, Tatiana Sokolova, Emilie Sapart, Laurent Meric de Bellefon, Adrien Nzeusseu, Christine Galant, Bernard Lauwerys, Patrick Durez","doi":"10.1186/s13075-024-03384-9","DOIUrl":"https://doi.org/10.1186/s13075-024-03384-9","url":null,"abstract":"Rheumatoid Arthritis (RA) often exhibits suboptimal treatment response despite early diagnosis and treatment. This study aimed to analyze Early Rheumatoid Arthritis (ERA) synovial biopsies through histology and immunohistochemistry (IHC) to identify predictive factors for treatment response to Methotrexate (MTX). 140 ERA patients from the UCLouvain Arthritis Cohort underwent synovial biopsy and were monitored after initiating Disease-Modifying Antirheumatic Drug (DMARD) therapy. Histological features [Synovial Hyperplasia, Fibrinoid Necrosis (FN), Hypervascularization and Inflammatory Infiltrate] and IHC (CD3, CD20, CD138, CD68) were each semi-quantitatively assessed on a 0–3 scale with 7 levels. A strong association was observed between synovial CD68 and Fibrinoid Necrosis scores [r = 0.44 (0.27 − 0.56); p < 0.0001]. CD68 correlated with C-Reactive Protein (CRP), DAS28, SDAI and CDAI. Fibrinoid Necrosis score correlated with CRP and DAS28. Patients were then categorized as CD68NecrosisHIGH (CD68 + Necrosis ≥ 3) and CD68NecrosisLOW (CD68 + Necrosis < 3). CD68NecrosisHIGH exhibited higher pre-treatment disease activity [5.48 (1.6) versus 4.8 (1.7); p = 0.03] and a greater fall in DAS28 [1.99 (2.06) versus 1.1 (2.27), p = 0.03], SDAI [21.45 (IQR 23.3) versus 11.65 (IQR 17.5); p = 0.003] and CDAI [16 [14.9] versus 10.5 (20.1), p = 0.04]. CD68NecrosisHIGH patients had a higher EULAR Moderate/Good Response rate. CD68Necrosis score was incorporated into a probability matrix model together with clinical features (SJC44 and DAS28) to predict achieving a Moderate/Good EULAR Response Criteria at 3 months with a good performance (AUC 0.724). FN and CD68 + in ERA synovial biopsies identify patients with higher disease activity and predict a better treatment response at three months. A model including synovial CD68 and fibrinoid necrosis with baseline clinical features predicts EULAR response at 3 months.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"27 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142002815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes 撤稿说明:成纤维细胞生长因子受体 1 是成纤维细胞生长因子 2 诱导人类关节软骨细胞分解代谢活动的主要原因
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-08-07 DOI: 10.1186/s13075-024-03381-y
Dongyao Yan, Di Chen, Simon M Cool, Andre J van Wijnen, Katalin Mikecz, Gillian Murphy, Hee-Jeong Im

Retraction Note: Arthritis Res Ther 13, R130 (2011)

https://doi.org/10.1186/ar3441

The Editors-in-Chief have retracted this article because an investigation jointly conducted by Rush University and the Jesse Brown Veterans Affairs Medical Center (JBVAMC) has determined that Fig. 5B contains fabricated and/or falsified data. Gillian Murphy agrees with this retraction. Simon M. Cool, Andre J. van Wijnen, Katalin Mikecz and Hee-Jeong Im have not responded to correspondence from the Publisher about this retraction. The Publisher has not been able to find current email addresees for Dongyao Yan and Di Chen.

Authors and Affiliations

  1. Department of Biochemistry, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL, 60612, USA

    Dongyao Yan, Di Chen & Hee-Jeong Im

  2. Department of Internal Medicine, Section of Rheumatology, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL, 60612, USA

    Hee-Jeong Im

  3. Orthopedic Surgery, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL, 60612, USA

    Katalin Mikecz & Hee-Jeong Im

  4. Department of Bioengineering, University of Illinois, 1304 West Springfield Avenue, Chicago, IL, 60612, USA

    Hee-Jeong Im

  5. Department of Stem Cells and Tissue Repair, Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06, Immunos, Singapore, 138648, Singapore

    Simon M Cool

  6. Division of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore

    Simon M Cool & Andre J van Wijnen

  7. Department of Cell Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA

    Andre J van Wijnen

  8. Department of Oncology, Cambridge University, Cancer Research Institute, Li Ka Shing Center, Robinson Way, CB2 ORE, Cambridge, 60612, UK

    Gillian Murphy

Authors
  1. Dongyao YanView author publications

    You can also search for this author in PubMed Google Scholar

  2. Di ChenView author publications

    You can also search for this author in PubMed Google Scholar

  3. Simon M CoolView author publications

    You can also search for this author in PubMed Google Scholar

  4. Andre J van WijnenView author publications

    You can also search for this author in PubMed Google Scholar

  5. Katalin MikeczView author publications

    You can also search for this author in PubMed Google Scholar

  6. Gillian MurphyView author publications

    You can also search for this author in PubMed Googl

撤稿说明:Arthritis Res Ther 13, R130 (2011)https://doi.org/10.1186/ar3441The 主编已撤回这篇文章,因为拉什大学和杰西-布朗退伍军人事务医疗中心(JBVAMC)联合进行的调查认定图 5B 包含捏造和/或篡改的数据。吉莉安-墨菲同意撤稿。Simon M. Cool、Andre J. van Wijnen、Katalin Mikecz 和 Hee-Jeong Im 没有回复出版商关于撤回声明的信件。出版商未能找到闫东耀和陈迪目前的电子邮件地址。作者和单位美国伊利诺伊州芝加哥市哈里森街 1735 号拉什大学医学中心生物化学系,邮编 60612;Hee-Jeong ImDepartment of Internal Medicine, Section of Rheumatology, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL, 60612, USAHee-Jeong ImOrthopedic Surgery, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL, 60612, USAKatalin Mikecz &;Hee-Jeong ImDepartment of Bioengineering, University of Illinois, 1304 West Springfield Avenue, Chicago, IL, 60612, USAHee-Jeong ImDepartment of Stem Cells and Tissue Repair, Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06, Immunos、新加坡,138648,SingaporeSimon M CoolDivision of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, SingaporeSimon M Cool &;Andre J van WijnenDepartment of Cell Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USAAndre J van WijnenDepartment of Oncology, Cambridge University, Cancer Research Institute, Li Ka Shing Center, Robinson Way, CB2 ORE, Cambridge, 60612、英国Gillian Murphy作者Dongyao Yan查看作者发表的论文您也可以在PubMed谷歌学术中搜索该作者Di Chen查看作者发表的论文您也可以在PubMed谷歌学术中搜索该作者Simon M Cool查看作者发表的论文您也可以在PubMed谷歌学术中搜索该作者ScholarAndre J van WijnenView 作者发表作品您也可以在 PubMed Google ScholarKatalin MikeczView 作者发表作品您也可以在 PubMed Google ScholarGillian MurphyView 作者发表作品您也可以在 PubMed Google ScholarHee-Jeong Im查看作者发表的作品您也可以在PubMed Google Scholar中搜索该作者通讯作者Hee-Jeong Im.出版商注释Springer Nature对出版地图中的管辖权主张和机构隶属关系保持中立。原文的在线版本可在https://doi.org/10.1186/ar3441。"本文已被撤回。更多详情,请参阅撤稿通知:https://doi.org/10.1186/s13075-024-03381-y "开放存取 本文采用知识共享署名-非商业性-禁止衍生 4.0 国际许可协议进行许可,该协议允许以任何媒介或格式进行任何非商业性使用、共享、分发和复制,只要您适当注明原作者和来源,提供知识共享许可协议的链接,并说明您是否修改了许可材料。根据本许可协议,您无权分享源自本文或本文部分内容的改编材料。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的信用栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,则您需要直接从版权所有者处获得许可。要查看该许可的副本,请访问 http://creativecommons.org/licenses/by-nc-nd/4.0/.Cite this articleYan, D., Chen, D., Cool, S.M. et al. Retraction Note: Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes.Arthritis Res Ther 26, 149 (2024). https://doi.org/10.1186/s13075-024-03381-yDownload citationPublished: 07 August 2024DOI: https://doi.org/10.1186/s13075-024-03381-yShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
{"title":"Retraction Note: Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes","authors":"Dongyao Yan, Di Chen, Simon M Cool, Andre J van Wijnen, Katalin Mikecz, Gillian Murphy, Hee-Jeong Im","doi":"10.1186/s13075-024-03381-y","DOIUrl":"https://doi.org/10.1186/s13075-024-03381-y","url":null,"abstract":"<p><b>Retraction Note: Arthritis Res Ther 13, R130 (2011)</b></p><p><b>https://doi.org/10.1186/ar3441</b></p><p>The Editors-in-Chief have retracted this article because an investigation jointly conducted by Rush University and the Jesse Brown Veterans Affairs Medical Center (JBVAMC) has determined that Fig. 5B contains fabricated and/or falsified data. Gillian Murphy agrees with this retraction. Simon M. Cool, Andre J. van Wijnen, Katalin Mikecz and Hee-Jeong Im have not responded to correspondence from the Publisher about this retraction. The Publisher has not been able to find current email addresees for Dongyao Yan and Di Chen.</p><h3>Authors and Affiliations</h3><ol><li><p>Department of Biochemistry, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL, 60612, USA</p><p>Dongyao Yan, Di Chen &amp; Hee-Jeong Im</p></li><li><p>Department of Internal Medicine, Section of Rheumatology, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL, 60612, USA</p><p>Hee-Jeong Im</p></li><li><p>Orthopedic Surgery, Rush University Medical Center, 1735 W Harrison Street, Chicago, IL, 60612, USA</p><p>Katalin Mikecz &amp; Hee-Jeong Im</p></li><li><p>Department of Bioengineering, University of Illinois, 1304 West Springfield Avenue, Chicago, IL, 60612, USA</p><p>Hee-Jeong Im</p></li><li><p>Department of Stem Cells and Tissue Repair, Institute of Medical Biology, A*STAR, 8A Biomedical Grove, #06-06, Immunos, Singapore, 138648, Singapore</p><p>Simon M Cool</p></li><li><p>Division of Musculoskeletal Oncology, Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore</p><p>Simon M Cool &amp; Andre J van Wijnen</p></li><li><p>Department of Cell Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA</p><p>Andre J van Wijnen</p></li><li><p>Department of Oncology, Cambridge University, Cancer Research Institute, Li Ka Shing Center, Robinson Way, CB2 ORE, Cambridge, 60612, UK</p><p>Gillian Murphy</p></li></ol><span>Authors</span><ol><li><span>Dongyao Yan</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Di Chen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Simon M Cool</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Andre J van Wijnen</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Katalin Mikecz</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Gillian Murphy</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Googl","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"84 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The mode of action of IL-23 in experimental inflammatory arthritic pain and disease IL-23 在实验性关节炎疼痛和疾病中的作用模式
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-08-06 DOI: 10.1186/s13075-024-03380-z
Kevin M.-C. Lee, Tanya Lupancu, Leon Chang, Carl L. Manthey, Martha Zeeman, Anne M. Fourie, John A. Hamilton
We have previously reported using gene-deficient mice that the interleukin (IL)-23p19 subunit is required for the development of innate immune-driven arthritic pain and disease. We aimed to explore here, using a number of in vivo approaches, how the IL-23p19 subunit can mechanistically control arthritic pain and disease in a T- and B- lymphocyte-independent manner. We used the zymosan-induced arthritis (ZIA) model in wild-type and Il23p19−/− mice, by a radiation chimera approach, and by single cell RNAseq and qPCR analyses, to identify the IL23p19-expressing and IL-23-responding cell type(s) in the inflamed joints. This model was also utilized to investigate the efficacy of IL-23p19 subunit blockade with a neutralizing monoclonal antibody (mAb). A novel IL-23-driven arthritis model was established, allowing the identification of putative downstream mediators of IL-23 in the control of pain and disease. Pain and arthritis were assessed by relative static weight distribution and histology, respectively. We present evidence that (i) IL-23p19+ non-bone marrow-derived macrophages are required for the development of ZIA pain and disease, (ii) prophylactic and therapeutic blockade of the IL-23p19 subunit ameliorate ZIA pain and disease and (iii) systemically administered IL-23 can induce arthritic pain and disease in a manner dependent on TNF, GM-CSF, CCL17 and cyclooxygenase activity, but independently of lymphocytes, CGRP, NGF and substance P. The data presented should aid IL-23 targeting both in the choice of inflammatory disease to be treated and the design of clinical trials.
我们以前曾利用基因缺陷小鼠报道过,白细胞介素(IL)-23p19 亚基是先天性免疫驱动的关节炎疼痛和疾病发展所必需的。我们的目的是在此使用多种体内方法探索 IL-23p19 亚基如何以一种独立于 T 淋巴细胞和 B 淋巴细胞的方式从机制上控制关节炎疼痛和疾病。我们在野生型和Il23p19-/-小鼠中使用了zymosan诱导的关节炎(ZIA)模型,通过辐射嵌合体方法以及单细胞RNAseq和qPCR分析,确定了发炎关节中表达IL23p19和IL-23反应的细胞类型。该模型还被用来研究用中和单克隆抗体(mAb)阻断IL-23p19亚基的疗效。建立了一种新型 IL-23 驱动的关节炎模型,从而确定了 IL-23 在控制疼痛和疾病方面的推定下游介质。疼痛和关节炎分别通过相对静态重量分布和组织学进行评估。我们提出的证据表明:(i) ZIA 疼痛和疾病的发生需要 IL-23p19+ 非骨髓来源的巨噬细胞;(ii) IL-23p19 亚基的预防性和治疗性阻断可改善 ZIA 疼痛和疾病;(iii) 系统给药 IL-23 可诱发关节炎疼痛和疾病,其方式依赖于 TNF、GM-CSF、CCL17 和环氧化酶活性,但独立于淋巴细胞、CGRP、NGF 和 P 物质。所提供的数据将有助于 IL-23 靶向治疗炎症性疾病和临床试验的设计。
{"title":"The mode of action of IL-23 in experimental inflammatory arthritic pain and disease","authors":"Kevin M.-C. Lee, Tanya Lupancu, Leon Chang, Carl L. Manthey, Martha Zeeman, Anne M. Fourie, John A. Hamilton","doi":"10.1186/s13075-024-03380-z","DOIUrl":"https://doi.org/10.1186/s13075-024-03380-z","url":null,"abstract":"We have previously reported using gene-deficient mice that the interleukin (IL)-23p19 subunit is required for the development of innate immune-driven arthritic pain and disease. We aimed to explore here, using a number of in vivo approaches, how the IL-23p19 subunit can mechanistically control arthritic pain and disease in a T- and B- lymphocyte-independent manner. We used the zymosan-induced arthritis (ZIA) model in wild-type and Il23p19−/− mice, by a radiation chimera approach, and by single cell RNAseq and qPCR analyses, to identify the IL23p19-expressing and IL-23-responding cell type(s) in the inflamed joints. This model was also utilized to investigate the efficacy of IL-23p19 subunit blockade with a neutralizing monoclonal antibody (mAb). A novel IL-23-driven arthritis model was established, allowing the identification of putative downstream mediators of IL-23 in the control of pain and disease. Pain and arthritis were assessed by relative static weight distribution and histology, respectively. We present evidence that (i) IL-23p19+ non-bone marrow-derived macrophages are required for the development of ZIA pain and disease, (ii) prophylactic and therapeutic blockade of the IL-23p19 subunit ameliorate ZIA pain and disease and (iii) systemically administered IL-23 can induce arthritic pain and disease in a manner dependent on TNF, GM-CSF, CCL17 and cyclooxygenase activity, but independently of lymphocytes, CGRP, NGF and substance P. The data presented should aid IL-23 targeting both in the choice of inflammatory disease to be treated and the design of clinical trials. ","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"55 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141895415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significant overlap of inflammatory and degenerative features on imaging among patients with degenerative disc disease, diffuse idiopathic skeletal hyperostosis and axial spondyloarthritis: a real-life cohort study 椎间盘退行性病变、弥漫性特发性骨骼增生症和轴性脊柱关节炎患者影像学检查中炎症和退行性病变特征的显著重叠:一项现实生活中的队列研究
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-08-03 DOI: 10.1186/s13075-024-03359-w
Nelly Ziade, Melanie Udod, Nikolaos Kougkas, Styliani Tsiami, Xenofon Baraliakos
Differentiating between degenerative disc disease (DDD), diffuse idiopathic skeletal hyperostosis (DISH), and axial spondyloarthritis (axSpA) represents a diagnostic challenge in patients with low back pain (LBP). We aimed to evaluate the distribution of inflammatory and degenerative imaging features in a real-life cohort of LBP patients referred to a tertiary university rheumatology center. In a retrospective cross-sectional analysis of patients referred for LBP, demographics, symptom information, and available imaging were collected. SpA-like changes were considered in the spine in the presence of one of the following lesions typically related to SpA: erosions, sclerosis, squaring, and syndesmophytes on conventional radiographs (CR) and bone marrow oedema (BMO), erosions, sclerosis, and fat lesions (FL) on MRI. SIJ CR were graded per New York criteria; on MRIs, SIJs were evaluated by quadrant for BMO, erosions, FL, sclerosis and ankylosis, similar to the approach used by the Berlin SIJ MRI scoring system. The final diagnosis made by the rheumatologist was the gold standard. Data were presented descriptively, by patient and by quadrant, and compared among the three diagnosis groups. Among 136 referred patients, 71 had DDD, 38 DISH, and 27 axSpA; median age 62 years [IQR55-73], 63% males. On CR, SpA-like changes were significantly higher in axSpA in the lumbar (50%, vs. DDD 23%, DISH 22%), in DISH in the thoracic (28%, vs. DDD 8%, axSpA 12%), and in DDD in the cervical spine (67% vs. DISH 0%, axSpA 33%). On MRI, BMO was significantly higher in DISH in the thoracic (37%, vs. DDD 22%, axSpA 5%) and equally distributed in the lumbar spine (35-42%). FL were significantly more frequently identified in DISH and axSpA in the thoracic (56% and 52%) and DDD and axSpA in the lumbar spine (65% and 74%, respectively). Degenerative changes were frequent in the three groups. Sacroiliitis (NY criteria) was identified in 49% (axSpA 76%, DDD 48%, DISH 29%). A significant overlap was found among DDD, DISH, and axSpA for inflammatory and degenerative imaging features. Particularly, SpA-like spine CR features were found in one-fourth of patients with DISH, and MRI BMO was found in one-third of those patients.
区分椎间盘退行性病变(DDD)、弥漫性特发性骨骼增生症(DISH)和轴性脊柱关节炎(axSpA)是腰背痛(LBP)患者的诊断难题。我们的目的是评估转诊到一所大学三级风湿病中心的腰背痛患者中炎症和退行性影像特征的分布情况。我们对转诊的腰椎间盘突出症患者进行了回顾性横断面分析,收集了人口统计学、症状信息和可用的影像学资料。如果脊柱出现以下与SpA相关的典型病变之一,则考虑为SpA样病变:常规X光片(CR)上的侵蚀、硬化、鳞状突起和联合骨赘,以及核磁共振成像(MRI)上的骨髓水肿(BMO)、侵蚀、硬化和脂肪病变(FL)。根据纽约标准对 SIJ CR 进行分级;在 MRI 上,按象限对 SIJ 的 BMO、侵蚀、FL、硬化和强直进行评估,这与柏林 SIJ MRI 评分系统所使用的方法类似。风湿免疫科医生的最终诊断是金标准。数据按患者和象限进行描述,并在三个诊断组之间进行比较。在136名转诊患者中,71人患有DDD,38人患有DISH,27人患有axSpA;中位年龄为62岁[IQR55-73],63%为男性。在 CR 上,腰椎 axSpA 的 SpA 样变明显较高(50%,DDD 23%,DISH 22%),胸椎 DISH 的 SpA 样变明显较高(28%,DDD 8%,axSpA 12%),颈椎 DDD 的 SpA 样变明显较高(67%,DISH 0%,axSpA 33%)。在核磁共振成像中,DISH 的胸椎 BMO 明显更高(37%,而 DDD 为 22%,axSpA 为 5%),腰椎的 BMO 分布相当(35-42%)。在胸椎的 DISH 和 axSpA(分别为 56% 和 52%)以及腰椎的 DDD 和 axSpA(分别为 65% 和 74%)中,发现 FL 的频率明显更高。退行性病变在三组中都很常见。49%的患者(axSpA 76%、DDD 48%、DISH 29%)患有骶髂关节炎(纽约标准)。DDD、DISH和axSpA的炎症和退行性影像学特征有明显重叠。特别是,在四分之一的 DISH 患者中发现了类似 SpA 的脊柱 CR 特征,在三分之一的患者中发现了 MRI BMO。
{"title":"Significant overlap of inflammatory and degenerative features on imaging among patients with degenerative disc disease, diffuse idiopathic skeletal hyperostosis and axial spondyloarthritis: a real-life cohort study","authors":"Nelly Ziade, Melanie Udod, Nikolaos Kougkas, Styliani Tsiami, Xenofon Baraliakos","doi":"10.1186/s13075-024-03359-w","DOIUrl":"https://doi.org/10.1186/s13075-024-03359-w","url":null,"abstract":"Differentiating between degenerative disc disease (DDD), diffuse idiopathic skeletal hyperostosis (DISH), and axial spondyloarthritis (axSpA) represents a diagnostic challenge in patients with low back pain (LBP). We aimed to evaluate the distribution of inflammatory and degenerative imaging features in a real-life cohort of LBP patients referred to a tertiary university rheumatology center. In a retrospective cross-sectional analysis of patients referred for LBP, demographics, symptom information, and available imaging were collected. SpA-like changes were considered in the spine in the presence of one of the following lesions typically related to SpA: erosions, sclerosis, squaring, and syndesmophytes on conventional radiographs (CR) and bone marrow oedema (BMO), erosions, sclerosis, and fat lesions (FL) on MRI. SIJ CR were graded per New York criteria; on MRIs, SIJs were evaluated by quadrant for BMO, erosions, FL, sclerosis and ankylosis, similar to the approach used by the Berlin SIJ MRI scoring system. The final diagnosis made by the rheumatologist was the gold standard. Data were presented descriptively, by patient and by quadrant, and compared among the three diagnosis groups. Among 136 referred patients, 71 had DDD, 38 DISH, and 27 axSpA; median age 62 years [IQR55-73], 63% males. On CR, SpA-like changes were significantly higher in axSpA in the lumbar (50%, vs. DDD 23%, DISH 22%), in DISH in the thoracic (28%, vs. DDD 8%, axSpA 12%), and in DDD in the cervical spine (67% vs. DISH 0%, axSpA 33%). On MRI, BMO was significantly higher in DISH in the thoracic (37%, vs. DDD 22%, axSpA 5%) and equally distributed in the lumbar spine (35-42%). FL were significantly more frequently identified in DISH and axSpA in the thoracic (56% and 52%) and DDD and axSpA in the lumbar spine (65% and 74%, respectively). Degenerative changes were frequent in the three groups. Sacroiliitis (NY criteria) was identified in 49% (axSpA 76%, DDD 48%, DISH 29%). A significant overlap was found among DDD, DISH, and axSpA for inflammatory and degenerative imaging features. Particularly, SpA-like spine CR features were found in one-fourth of patients with DISH, and MRI BMO was found in one-third of those patients.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"21 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141880328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies CD163 和主要组织相容性复合体 I 类的表达作为特发性炎症性肌病的诊断标志物
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-07-30 DOI: 10.1186/s13075-024-03364-z
Byeongzu Ghang, So Hye Nam, Wonho Choi, Hwa Jung Kim, Jungsun Lee, Doo-Ho Lim, Soo Min Ahn, Ji Seon Oh, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee, Jinseok Kim, Bin Yoo, Soo Jeong Nam
To develop an inflammation-related immunohistochemistry marker-based algorithm that confers higher diagnostic ability for idiopathic inflammatory myopathies (IIMs) than IIM-related histopathologic features. Muscle biopsy tissues from 129 IIM patients who met the 2017 EULAR/ACR criteria and 73 control tissues from patients with non-inflammatory myopathies or healthy muscle specimens were evaluated for histological features and immunostaining results of CD3, CD4, CD8, CD20, CD68, CD163, MX1, MHC class I, MHC class II, and HLA-DR. Diagnostic algorithms for IIM were developed based on the results of the classification and regression tree (CART) analysis, which used immunostaining results as predictor variables for classifying patients with IIMs. In the analysis set (IIM, n = 129; control, n = 73), IIM-related histopathologic features had a diagnostic accuracy of 87.6% (sensitivity 80.6%; specificity 100.0%) for IIMs. Notably, muscular expression of CD163 (99.2% vs. 20.8%, p < 0.001) and MHC class I (87.6% vs. 23.1%, p < 0.001) was significantly higher in the IIM group than in controls. Based on the CART analysis results, we developed an algorithm combining CD163 and MHC class I expression that conferred a diagnostic accuracy of 95.5% (sensitivity 96.1%; specificity 94.5%). In addition, our algorithm was able to correctly diagnose IIM in 94.1% (16/17) of patients who did not meet the 2017 EUALR/ACR criteria but were diagnosed as having IIMs by an expert physician. Combination of CD163 and MHC class I muscular expression may be useful in diagnosing IIMs.
目的:开发一种基于炎症相关免疫组化标记物的算法,与特发性炎症性肌病(IIM)相关组织病理学特征相比,该算法具有更高的特发性炎症性肌病诊断能力。对符合2017年EULAR/ACR标准的129例特发性炎症性肌病患者的肌肉活检组织和非炎症性肌病患者或健康肌肉标本的73例对照组织进行了组织学特征和CD3、CD4、CD8、CD20、CD68、CD163、MX1、MHC I类、MHC II类和HLA-DR的免疫染色结果评估。根据分类和回归树(CART)分析的结果制定了 IIM 的诊断算法,该算法将免疫染色结果作为 IIM 患者分类的预测变量。在分析集(IIM,n = 129;对照组,n = 73)中,IIM 相关组织病理学特征对 IIM 的诊断准确率为 87.6%(灵敏度 80.6%;特异性 100.0%)。值得注意的是,IIM 组中 CD163(99.2% 对 20.8%,P<0.001)和 MHC I 类(87.6% 对 23.1%,P<0.001)的肌肉表达明显高于对照组。根据 CART 分析结果,我们开发了一种结合 CD163 和 MHC I 类表达的算法,其诊断准确率为 95.5%(灵敏度 96.1%;特异性 94.5%)。此外,我们的算法还能对94.1%(16/17)不符合2017年EUALR/ACR标准但被专家医生诊断为患有IIM的患者正确诊断出IIM。结合CD163和MHC I类肌肉表达可能有助于诊断IIM。
{"title":"Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies","authors":"Byeongzu Ghang, So Hye Nam, Wonho Choi, Hwa Jung Kim, Jungsun Lee, Doo-Ho Lim, Soo Min Ahn, Ji Seon Oh, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee, Jinseok Kim, Bin Yoo, Soo Jeong Nam","doi":"10.1186/s13075-024-03364-z","DOIUrl":"https://doi.org/10.1186/s13075-024-03364-z","url":null,"abstract":"To develop an inflammation-related immunohistochemistry marker-based algorithm that confers higher diagnostic ability for idiopathic inflammatory myopathies (IIMs) than IIM-related histopathologic features. Muscle biopsy tissues from 129 IIM patients who met the 2017 EULAR/ACR criteria and 73 control tissues from patients with non-inflammatory myopathies or healthy muscle specimens were evaluated for histological features and immunostaining results of CD3, CD4, CD8, CD20, CD68, CD163, MX1, MHC class I, MHC class II, and HLA-DR. Diagnostic algorithms for IIM were developed based on the results of the classification and regression tree (CART) analysis, which used immunostaining results as predictor variables for classifying patients with IIMs. In the analysis set (IIM, n = 129; control, n = 73), IIM-related histopathologic features had a diagnostic accuracy of 87.6% (sensitivity 80.6%; specificity 100.0%) for IIMs. Notably, muscular expression of CD163 (99.2% vs. 20.8%, p < 0.001) and MHC class I (87.6% vs. 23.1%, p < 0.001) was significantly higher in the IIM group than in controls. Based on the CART analysis results, we developed an algorithm combining CD163 and MHC class I expression that conferred a diagnostic accuracy of 95.5% (sensitivity 96.1%; specificity 94.5%). In addition, our algorithm was able to correctly diagnose IIM in 94.1% (16/17) of patients who did not meet the 2017 EUALR/ACR criteria but were diagnosed as having IIMs by an expert physician. Combination of CD163 and MHC class I muscular expression may be useful in diagnosing IIMs.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"8 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Arthritis Research & Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1